August 1997
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS32
Academic Journal
Presents an abstract of the research manuscript `Safety of full dose anticoagulation in autologous stem cell transplantation,' by A. Schimmer, J. MacKinnon et al from the University of Toronto.


Related Articles

  • Acute graft-versus-host disease (aGVHD) presenting with an acquired lupus anticoagulant. Kharfan-Dabaja, M A; Morgensztern, D; Santos, E; Goodman, M; Fernandez, H F // Bone Marrow Transplantation;1/15/2003, Vol. 31 Issue 2, p129 

    There are few reports describing the association between antiphospholipid antibodies, including the lupus anticoagulant, and bone marrow or peripheral stem cell transplantation. Autoimmune syndromes and autoantibodies such as lupus anticoagulant and anticardiolipin antibodies have been described...

  • Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature. Ibrahim, R. B.; Peres, E.; Dansey, R.; Abidi, M. H.; Abella, E. M.; Gumma, M. M.; Milan, N.; Smith, D. W.; Heilbrun, L. K.; Klein, J. // Bone Marrow Transplantation;Jun2005, Vol. 35 Issue 11, p1071 

    Summary:Few attempts have been made to examine the feasibility of safely administering low-molecular-weight-heparins (LMWHs) in the presence of concurrent thrombocytopenia. We retrospectively investigated the safety of low-dose LMWH in BMT patients, a population at risk of bleeding. In total, 26...

  • An optimization of hematopoietic stem and progenitor cell isolation for scientific and clinical purposes by the application of a new parameter determining the hematopoietic graft efficacy. Baumert, B.; Grymuła, K.; Pietruszka, D.; Kotowski, M.; Mielczarek, M.; Dziedziejko, V.; Hałasa, M.; Czerny, B.; Walczak, M.; Machaliński, B. // Folia Histochemica et Cytobiologica;2008, Vol. 46 Issue 3, p299 

    The transplantation of hematopoietic stem and progenitor cells (HSPC) is an established lifesaving therapy. Bone marrow (BM), harvested from heparinized cadaveric organ donors, peripheral blood (PB) and cord blood (CB), are important sources of hematopoietic stem cells. HSPCs, which are used for...

  • Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT: is it still reasonable to use t-PA? Yoon, J-H; Min, W-S; Kim, H-Je; Kim, J-H; Shin, S-H; Yahng, S-A; Lee, S-E; Cho, B-S; Eom, K-S; Kim, Y-J; Lee, S; Min, C-K; Cho, S-G; Kim, D-W; Lee, J-W; Park, C-W // Bone Marrow Transplantation;Dec2013, Vol. 48 Issue 12, p1562 

    Hepatic veno-occlusive disease (VOD) remains one of the most severe complications of hematopoietic SCT (HSCT). Anticoagulation and thrombolytic therapies using tissue-plasminogen activator (t-PA) have been used, but are reported to be ineffective and are associated with significant bleeding...

  • Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. Imran, H.; Tleyjeh, I. M.; Zirakzadeh, A.; Rodriguez, V.; Khan, S. P. // Bone Marrow Transplantation;Apr2006, Vol. 37 Issue 7, p677 

    Hepatic veno-occlusive disease is a serious regimen-related toxicity in patients undergoing hematopoietic stem cell transplantation. We performed a systematic review and meta-analysis of the literature on the effect of anticoagulation in preventing veno-occlusive disease. Several databases and...

  • Busulfan.  // Reactions Weekly;9/29/2012, Issue 1421, p15 

    The article describes several cases of patients with haematological malignancies who developed late-onset veno-occlusive disease (VOD) or sinusoidal obstruction (SOS) after receiving treatment with busulfan and haemotopoietic cell transplant (HCT). All patients underwent conditioning...

  • Kinetics of IL-7 and IL-15 Levels after Allogeneic Peripheral Blood Stem Cell Transplantation following Nonmyeloablative Conditioning. De Bock, Muriel; Fillet, Marianne; Hannon, Muriel; Seidel, Laurence; Merville, Marie-Paule; Gothot, André; Beguin, Yves; Baron, Frédéric // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    Background: We analysed kinetics of IL-7 and IL-15 levels in 70 patients given peripheral blood stem cells after nonmyeloablative conditioning. Methods: EDTA-anticoagulated plasma and serum samples were obtained before conditioning and about once per week after transplantation until day...

  • Cell therapy for cystinosis.  // Current Medical Literature: Lysosomal Storage Disease;2011, Vol. 9 Issue 1, p28 

    In this article the author comments on a study about the stem cell transplantation in a murine model of cystinosis.

  • Tell Me More. Mettenburg, Julie // Countdown;Winter2000, Vol. 21 Issue 1, p40 

    Provides answers to readers' questions about diabetes. Barriers in the consideration of stem cell transplantation as a possible cure for diabetes; Research about genes called HLA markers which are associated with risk for diabetes.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics